322
Participants
Start Date
May 11, 2021
Primary Completion Date
August 5, 2023
Study Completion Date
September 28, 2023
CBP-201
CBP-201 subcutaneous (SC) injection.
Placebo
Placebo subcutaneous (SC) injection.
Connect Investigative Site 304, Püspökladány
Connect Investigative Site 303, Szombathely
Connect Investigative Site 153, New York
Connect Investigative Site 220, Shenyang
Connect Investigative Site 503, Seongnam-si
Connect Investigative Site 214, Baotou
Connect Investigative Site 117, Buffalo
Connect Investigative Site 120, White Marsh
Connect Investigative Site 505, Incheon
Connect Investigative Site 122, Winston-Salem
Connect Investigative Site 123, Winter Park
Connect Investigative Site 161, Hialeah
Connect Investigative Site 165, Miami Gardens
Connect Investigative Site 110, Miami Lakes
Connect Investigative Site 114, Hollywood
Connect Investigative Site 104, Miami
Connect Investigative Site 166, Miami
Connect Investigative Site 118, Miami
Connect Investigative Site 162, Miami
Connect Investigative Site 163, Miami
Connect Investigative Site 164, Miami
Connect Investigative Site 105, Miami
Connect Investigative Site 142, Leesburg
Connect Investigative Site 147, Toledo
Connect Investigative Site 136, Cincinnati
Connect Investigative Site 146, West Bloomfield
Connect Investigative Site 112, St Louis
Connect Investigative Site 107, Edmond
Connect Investigative Site 149, Oklahoma City
Connect Investigative Site 121, Dallas
Connect Investigative Site 150, Katy
Connect Investigative Site 102, Boerne
Connect Investigative Site 119, Bellevue
Connect Investigative Site 116, Austin
Connect Investigative Site 108, El Paso
Connect Investigative Site 154, Tucson
Connect Investigative Site 144, North Las Vegas
Connect Investigative Site 109, Huntington Beach
Connect Investigative Site 143, Huntington Beach
Connect Investigative Site 125, Mission Viejo
Connect Investigative Site 132, Lancaster
Connect Investigative Site 103, San Jose
Connect Investigative Site 201, Beijing
Connect Investigative Site 216, Beijing
Connect Investigative Site 209, Beijing
Connect Investigative Site 215, Beijing
Connect Investigative Site 212, Changchun
Connect Investigative Site 207, Shanghai
Connect Investigative Site 218, Shanghai
Connect Investigative Site 205, Wuxi
Connect Investigative Site 208, Yangzhou
Connect Investigative Site 206, Bengbu
Connect Investigative Site 217, Ningbo
Connect Investigative Site 202, Changsha
Connect Investigative Site 213, Wuhan
Connect Investigative Site 211, Luoyang
Connect Investigative Site 203, Guangzhou
Connect Investigative Site 224, Ürümqi
Connect Investigative Site 124, Bangor
Connect Investigative Site 111, Princeton
Connect Investigative Site 129, Warwick
Connect Investigative Site 204, Baotou
Connect Investigative Site 210, Hohhot
Connect Investigative Site 221, Taiyuan
Connect Investigative Site 222, Taiyuan
Connect Investigative Site 402, Krakow
Connect Investigative Site 401, Krakow
Connect Investigative Site 403, Lubin
Connect Investigative Site 408, Wroclaw
Connect Investigative Site 406, Skierniewice
Connect Investigative Site 404, Bialystok
Connect Investigative Site 405, Bialystok
Connect Investigative Site 410, Częstochowa
Connect Investigative Site 407, Skarżysko-Kamienna
Connect Investigative Site 501, Seoul
Connect Investigative Site 502, Seoul
Lead Sponsor
Connect Biopharm LLC
INDUSTRY